Compare · ELV vs YDES
ELV vs YDES
Side-by-side comparison of Elevance Health Inc. (ELV) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $92.91B, about 194.6x YDES ($477.4M).
- Over the past year, ELV is up 20.9% and YDES is down 69.9% - ELV leads by 90.8 points.
- Both names hit the wire about 3 times in the past 4 weeks.
- ELV has more recent analyst coverage (23 ratings vs 0 for YDES).
PerformanceELV+20.95%YDES-69.86%
2025-10-20+0.00%2026-10-16
- Company
- Elevance Health Inc.
- YD Bio Limited
- Price
- $428.56+0.04%
- $6.04-9.64%
- Market cap
- $92.91B
- $477.4M
- 1M return
- +3.42%
- +76.50%
- 1Y return
- +20.95%
- -69.86%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 3
- 3
- Recent ratings
- 23
- 0
ELV
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest ELV
- SEC Form 4 filed by Elevance Health Inc.
- Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
- Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 349 shares, decreasing direct ownership by 5% to 7,230 units (SEC Form 4)
- EVP & Chief HR Officer Craig Ryan R covered exercise/tax liability with 144 shares, decreasing direct ownership by 2% to 6,530 units (SEC Form 4)
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
Latest YDES
- SEC Form 4 filed by YD Bio Limited
- SEC Form 4 filed by YD Bio Limited
- YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
- CEO Shen Ethan Phd bought $48,895 worth of Ordinary Shares (12,700 units at $3.85), increasing direct ownership by 0.11% to 11,258,331 units (SEC Form 4)
- CEO Shen Ethan Phd bought $12,183 worth of Ordinary Shares (3,100 units at $3.93), increasing direct ownership by 0.03% to 11,245,631 units (SEC Form 4)
- CEO Shen Ethan Phd bought $67,447 worth of Ordinary Shares (18,378 units at $3.67), increasing direct ownership by 0.16% to 11,242,531 units (SEC Form 4)
- YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
- YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
- SEC Form 424B3 filed by YD Bio Limited
- SEC Form 6-K filed by YD Bio Limited